At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cannabidiol in the Treatment of Opioid Use Disorder
In Brief
A Phase 2 clinical trial evaluating Placebo, Cannabidiol (CBD) 200mg, and 1 other intervention for Opioid Use Disorder. Completed, enrolled 76 participants across 1 site.
Signals
Detailed Summary
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of our project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of CBD. This next phase is to determine whether CBD can serve as a potential adjunct treatment to reduce craving and anxiety in individuals with OUD maintained on opioid agonist therapy.
Study Details
Timeline
Arms & Interventions
CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
Matching placebo.in first dosing period and CBD 400mg in second dosing period
CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
Matching placebo.in first dosing period and CBD 400mg in second dosing period
Interventions
Matching placebo twice daily for first 4 weeks
First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.